Marco Colleoni

Marco Colleoni

UNVERIFIED PROFILE

Are you Marco Colleoni?   Register this Author

Register author
Marco Colleoni

Marco Colleoni

Publications by authors named "Marco Colleoni"

Are you Marco Colleoni?   Register this Author

100Publications

3716Reads

32Profile Views

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

J Clin Oncol 2019 Oct 16:JCO1801967. Epub 2019 Oct 16.

International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01967DOI Listing
October 2019

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

N Engl J Med 2019 07 4;381(4):307-316. Epub 2019 Jun 4.

From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) - all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (A.B.); the Breast Center, Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Munich, Germany (N.H.); the Division of Medical Senology, Istituto Europeo di Oncologia, Milan (M.C.); Hospital de Caridade de Ijuí, CACON, Ijuí, Brazil (F.F.); the Organisation for Oncology and Translational Research, Hong Kong (L.C.); Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico (S.C.-G.); Institut Català d'Oncologia, Hospital de Sant Joan Despí Moisès Broggi, Barcelona (R.V.-V.); Novartis Pharmaceuticals, East Hanover, NJ (A.C., K.R.-L., T.T.); Novartis, Basel, Switzerland (G.H., I.G.); the UCLA Jonsson Comprehensive Cancer Center, Los Angeles (S.H.); and the University of Texas M.D. Anderson Cancer Center, Houston (D.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1903765DOI Listing
July 2019

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2018 Nov 20;379(20):1926-1936. Epub 2018 Oct 20.

From the Institute of Cancer Research and Royal Marsden Hospital, London (N.C.T.); David Geffen School of Medicine at University of California, Los Angeles, Santa Monica (D.J.S.), and Pfizer Oncology, San Diego (X.H.) - both in California; National Cancer Center, Goyang-si, Gyeonggi-do (J.R.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.) - both in South Korea; Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine (I.B.); National Hospital Organization Osaka National Hospital, Osaka (N.M.), and Aichi Cancer Center Hospital, Nagoya (H.I.) - both in Japan; Istituto Europeo di Oncologia (M. Colleoni) and Pfizer Oncology (C.G.) - both in Milan; Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.), and Pfizer Oncology, Collegeville (C.H.B.) - both in Pennsylvania; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (S.V.); Brustzentrum der Universität München, Munich (N.H.), and the German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Institut Gustave Roussy, Villejuif, France (F.A.); Pfizer Oncology, Cambridge, MA (K.P.T.); and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago (M. Cristofanilli).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810527
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810527DOI Listing
November 2018

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

J Clin Oncol 2018 07 20;36(19):1941-1948. Epub 2018 Apr 20.

Mitch Dowsett and Andrew Dodson, Royal Marsden Hospital; Mitch Dowsett, Institute of Cancer Research; Ivana Sestak and Jack Cuzick, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom; Meredith M. Regan, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA; Giuseppe Viale, University of Milan; Guiseppe Viale and Marco Colleoni, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital St Gallen, St Gallen, and International Breast Cancer Study Group and Swiss Group for Clinical Cancer Research, Berne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049399PMC
July 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes.

Clin Breast Cancer 2018 06 10;18(3):e401-e405. Epub 2017 Jul 10.

Division of Medical Senology, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2017.07.003DOI Listing
June 2018

Optimal management of luminal breast cancer: how much endocrine therapy is long enough?

Ther Adv Med Oncol 2018 18;10:1758835918777437. Epub 2018 Jun 18.

Division of Medical Senology, European Institute of Oncology, Via Ripamonti, 435, Milano 20141, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918777437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024281PMC
June 2018

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

J Clin Oncol 2017 Sep 27;35(27):3113-3122. Epub 2017 Jun 27.

Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.0946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597253PMC
September 2017

Metronomics in the neoadjuvant and adjuvant treatment of breast cancer.

Cancer Lett 2017 08 16;400:259-266. Epub 2017 Jan 16.

Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.12.041DOI Listing
August 2017

Reply to L. Moscetti.

J Clin Oncol 2017 05 17;35(14):1628. Epub 2017 Jan 17.

Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5730DOI Listing
May 2017

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

J Clin Oncol 2017 Apr 13;35(11):1179-1188. Epub 2017 Feb 13.

Signe Borgquist and Judy E. Garber, Dana-Farber Cancer Institute, Harvard Medical School; Anita Giobbie-Hurder, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Richard D. Gelber, IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, T.H. Chan Harvard School of Public Health, and Frontier Science and Technology Research Foundation; Karen N. Price, IBCSG Statistical Center and Frontier Science and Technology Research Foundation; Meredith M. Regan, IBCSG Statistical Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Signe Borgquist, Lund University, Lund, Sweden; Thomas P. Ahern, University of Vermont, Burlington, VT; Marco Colleoni and Aron Goldhirsch, IBCSG and European Institute of Oncology, Milan, Italy; István Láng, IBCSG and National Institute of Oncology, Budapest, Hungary; Marc Debled, Institut Bergonié, Bordeaux, France; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Roger von Moos, Cantonal Hospital Graubuenden, Chur; Swiss Group for Clinical Cancer Research and IBCSG; Manuela Rabaglio, IBCSG Coordinating Center and Inselspital, Bern; Beat Thürlimann, Breast Center St. Gallen, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Research and IBCSG, Bern, Switzerland; Ian Smith, The Royal Marsden Hospital, London, United Kingdom; and Alan S. Coates, IBCSG and University of Sydney School of Public Health, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.3116DOI Listing
April 2017

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

J Clin Oncol 2016 10 20;34(28):3400-8. Epub 2016 Jun 20.

Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.6595
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035120PMC
http://dx.doi.org/10.1200/JCO.2015.65.6595DOI Listing
October 2016

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

J Clin Oncol 2016 07 4;34(19):2221-31. Epub 2016 Apr 4.

Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/03/31/JCO.2015.64
Web Search
http://dx.doi.org/10.1200/JCO.2015.64.3171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962708PMC
July 2016

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

J Clin Oncol 2016 07 23;34(21):2452-9. Epub 2016 May 23.

Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.8619DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962733PMC
July 2016

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

J Clin Oncol 2016 05 28;34(14):1601-10. Epub 2016 Mar 28.

Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Brea

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872319PMC
May 2016

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.

J Clin Oncol 2016 Mar 19;34(9):927-35. Epub 2016 Jan 19.

Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.3504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933127PMC
March 2016

Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care.

Authors:
Marco Colleoni

Lancet Oncol 2016 Mar 8;17(3):265-6. Epub 2016 Feb 8.

Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan 20141, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00566-5DOI Listing
March 2016

Clinical overview of metronomic chemotherapy in breast cancer.

Nat Rev Clin Oncol 2015 Nov 4;12(11):631-44. Epub 2015 Aug 4.

Division of Medical Senology and International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.131DOI Listing
November 2015

Picking the optimal endocrine adjuvant treatment for pre-menopausal women.

Breast 2015 Nov 4;24 Suppl 2:S11-4. Epub 2015 Aug 4.

Division of Medical Senology, European Institute of Oncology, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.004DOI Listing
November 2015

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

J Clin Oncol 2015 Sep 27;33(25):2772-9. Epub 2015 Jul 27.

Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550691PMC
September 2015

Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.

Drugs 2015 Aug;75(12):1311-21

Division of Medical Senology, and International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-015-0433-7DOI Listing
August 2015

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease.

Ecancermedicalscience 2015 9;9:544. Epub 2015 Jun 9.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA ; International Breast Cancer Study Group (IBCSG), Effingerstrasse 40, Bern 3008, Switzerland.

View Article

Download full-text PDF

Source
http://www.ecancer.org/journal/9/full/544-improved-adjuvant-
Publisher Site
http://dx.doi.org/10.3332/ecancer.2015.544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462884PMC
June 2015

Sarcoidosis with bone involvement mimicking metastatic disease at (18)F-FDG PET/CT: problem solving by diffusion whole-body MRI.

Ecancermedicalscience 2015 7;9:537. Epub 2015 May 7.

Division of Radiology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2015.537DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435754PMC
May 2015

Metronomic therapy and breast cancer: a systematic review.

Cancer Treat Rev 2014 Sep 18;40(8):942-50. Epub 2014 Jun 18.

Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.06.002DOI Listing
September 2014

Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs.

Clin Breast Cancer 2014 Aug 2;14(4):285-90. Epub 2014 Mar 2.

Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2014.02.010DOI Listing
August 2014

Targeting bone metastatic cancer: Role of the mTOR pathway.

Biochim Biophys Acta 2014 Apr 5;1845(2):248-54. Epub 2014 Feb 5.

Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2014.01.009DOI Listing
April 2014

Time to initiation of adjuvant chemotherapy for early breast cancer and outcome: the earlier, the better?

J Clin Oncol 2014 Mar 10;32(8):717-9. Epub 2014 Feb 10.

International Breast Cancer Study Group; European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.3942DOI Listing
March 2014

Neoadjuvant chemotherapy for breast cancer: any progress?

Lancet Oncol 2014 Feb 19;15(2):131-2. Epub 2013 Dec 19.

International Breast Cancer Study Group and Breast Health Program, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70584-9DOI Listing
February 2014

Debate: The biology of breast cancer in young women is unique.

Oncologist 2013 ;18(4):e13-5

Division of Medical Senology, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639538PMC
December 2013

The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?

Cancer Treat Rev 2013 Dec 29;39(8):886-90. Epub 2013 May 29.

Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.04.007DOI Listing
December 2013

Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?

Breast 2013 Dec 30;22(6):1046-51. Epub 2013 Sep 30.

Division of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776130024
Publisher Site
http://dx.doi.org/10.1016/j.breast.2013.08.006DOI Listing
December 2013

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Breast 2013 Dec 2;22(6):1094-100. Epub 2013 Oct 2.

International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855346PMC
December 2013

Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.

Breast Cancer Res Treat 2013 Nov 7;142(2):455-9. Epub 2013 Nov 7.

Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, 6500, Bellinzona, Switzerland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2757-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921668PMC
November 2013

PET/CT and breast cancer subtypes.

Eur J Nucl Med Mol Imaging 2013 Sep;40(9):1301-3

Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-013-2472-1DOI Listing
September 2013

Tailoring adjuvant treatments for the individual patient with luminal breast cancer.

Hematol Oncol Clin North Am 2013 Aug 18;27(4):703-14, vii-viii. Epub 2013 Jun 18.

Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.05.012DOI Listing
August 2013

Extended adjuvant chemotherapy in endocrine non-responsive disease.

Breast 2013 Aug;22 Suppl 2:S161-4

Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.07.031DOI Listing
August 2013

Immunohistochemically defined subtypes and outcome of apocrine breast cancer.

Clin Breast Cancer 2013 Apr 14;13(2):95-102. Epub 2012 Dec 14.

Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.11.004DOI Listing
April 2013